MRTX — Mirati Therapeutics Share News
0.000.00%
Last trade - 00:00- $4.12bn
- $3.15bn
- $12.44m
EU regulator declines to back Mirati's lung cancer drug
U.S. RESEARCH ROUNDUP-Analog Devices, Microsoft, Workday
U.S. RESEARCH ROUNDUP-Annexon, Nvidia, Southwestern Energy
Brief: Mirati Therapeutics Provides Update On The Phase 3 Study Evaluating Sitravatinib In Combination With Opdivo®
Mirati Therapeutics falls as cancer therapy fails in late-stage study
Mirati Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Brief: Mirati Therapeutics Reports First Quarter 2023 Financial Results And Recent Corporate Updates
Brief: Mirati Therapeutics posts Q1 basic EPS USD -3.18
Mirati Therapeutics Inc expected to post a loss of $3.55 a share - Earnings Preview
Brief: Journal Of Clinical Oncology Publishes Rapid Communication Featuring Updated Clinical Data For Adagrasib As A Targeted Treatment For Krasg12c-Mutated Advanced Solid Tumors
Brief: Mirati Therapeutics Reports Fourth Quarter And Full Year 2022 Financial Results And Recent Corporate Updates
Mirati Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Mirati Therapeutics Inc expected to post a loss of $3.55 a share - Earnings Preview
Mirati Therapeutics rises on FDA nod for tumor therapy trial
Brief: Mirati Announces IND Clearance By U.S. FDA
U.S. STOCKS ON THE MOVE-ProQR Therapeutics, IsoPlexis Corp, Tesla, AMC Entertainment
U.S. STOCKS ON THE MOVE-Mirati Therapeutics, CarMax, ORIC Pharmaceuticals
Mirati gains on FDA's 'breakthrough therapy' tag for colon cancer treatment
Brief: Mirati Therapeutics Announces Adagrasib (Krazati™) Receives Breakthrough Therapy Designation From FDA For Patients With Advanced, Kras-Mutated Colorectal Cancer